Patents Assigned to Detroit R & D
-
Patent number: 11519922Abstract: This invention discloses diagnosis of risk of chemotherapy-induced cardiotoxicity by measurement of increased expression of soluble epoxide hydrolase in vitro and in vivo in cells, tissues or animals including measurement of increased levels of soluble epoxide hydrolase metabolites, e.g., 14,15-DHET and 11,12-DHET, in biological fluids. This invention also includes diagnosis of risk of chemotherapy-induced cardiotoxicity by measuring increased levels of oxidative stress in cells, tissues or animals including measurement of increased levels of oxidative stress biomarkers, e.g., 8-isoprostane, in biological fluids. Fatty acid and protein biomarkers to diagnose the risk of chemotherapy-induced cardiotoxicity are detected using various detection methods including mass spectrometry and immunoassay such as ELISA, Western blot analysis or label-free microwell and nanowell technologies.Type: GrantFiled: January 28, 2019Date of Patent: December 6, 2022Assignee: Detroit R&D, Inc.Inventor: Hyesook Kim
-
Publication number: 20220276265Abstract: This invention discloses diagnosis of risk of chemotherapy-induced cardiotoxicity by measurement of increased expression of soluble epoxide hydrolase in vitro and in vivo in cells, tissues or animals including measurement of increased levels of soluble epoxide hydrolase metabolites, e.g., 14,15-DHET and 11,12-DHET, in biological fluids. This invention also includes diagnosis of risk of chemotherapy-induced cardiotoxicity by measuring increased levels of oxidative stress in cells, tissues or animals including measurement of increased levels of oxidative stress biomarkers, e.g., 8-isoprostane, in biological fluids. Fatty acid and protein biomarkers to diagnose the risk of chemotherapy-induced cardiotoxicity are detected using various detection methods including mass spectrometry and immunoassay such as ELISA, Western blot analysis or label-free microwell and nanowell technologies.Type: ApplicationFiled: January 28, 2019Publication date: September 1, 2022Applicant: Detroit R & D, Inc.Inventor: Hyesook Kim
-
Publication number: 20200378950Abstract: A method of characterizing the protein O-GlcNAcylation site-specificity of an antibody. A method of detecting or quantifying the expression of site-specific O-GlcNAcylated proteins expressed in cells and biological samples. A method of diagnosing cancer in a host based on the cellular expression of site-specific O-GlcNAcylated proteins. A method of screening anti-cancer compounds according to their ability to increase a level O-GlcNAcylation of oncogene or tumor suppressor proteins. Methods of treating cancer in an animal host by administering compounds that increase a level of O-GlcNAcylated c-myc or p53 in cancer cells. A method of distinguishing subclasses of pancreatic cancer according to the sensitivity of pancreatic cancer cells to an imidazole derivative, and a method of personalized pancreatic cancer treatment delivered according to the sensitivity subclasses.Type: ApplicationFiled: May 27, 2019Publication date: December 3, 2020Applicant: Detroit R & D, Inc.Inventors: Hyesook Kim, So Hee Kim
-
Publication number: 20200241019Abstract: This invention discloses diagnosis of risk of chemotherapy-induced cardiotoxicity by measurement of increased expression of soluble epoxide hydrolase in vitro and in vivo in cells, tissues or animals including measurement of increased levels of soluble epoxide hydrolase metabolites, e.g., 14,15-DHET and 11,12-DHET, in biological fluids. This invention also includes diagnosis of risk of chemotherapy-induced cardiotoxicity by measuring increased levels of oxidative stress in cells, tissues or animals including measurement of increased levels of oxidative stress biomarkers, e.g., 8-isoprostane, in biological fluids. Fatty acid and protein biomarkers to diagnose the risk of chemotherapy-induced cardiotoxicity are detected using various detection methods including mass spectrometry and immunoassay such as ELISA, Western blot analysis or label-free microwell and nanowell technologies.Type: ApplicationFiled: January 28, 2019Publication date: July 30, 2020Applicant: Detroit R & D, Inc.Inventor: Hyesook Kim
-
Publication number: 20190227023Abstract: The present invention provides a method of obtaining miRNA biomarkers by data-search of up-regulated microRNAs (miRNAs) in cancer and screening the miRNA biomarkers to identify cancer kind- and stage-specific miRNA biomarker(s) using cancer cells, tissues and biological fluids. This invention includes obtaining lung cancer-specific miRNA biomarkers including early (Stage I) lung cancer miRNA biomarkers and identification of anti-cancer miRNA (complementary miRNA, DNA and their derivatives) in order to ameliorate diseases. This invention relates to novel utility of nanowell electrodes to detect target molecules in biological samples. The invention teaches methods to increase sensitivity of nanowell electrodes to detect target molecules including miRNA, RNA and DNA in biological samples to diagnose cancer and other diseases and monitoring prognosis and response to therapy.Type: ApplicationFiled: December 21, 2017Publication date: July 25, 2019Applicant: Detroit R&D, Inc.Inventor: Hyesook Kim
-
Patent number: 10317409Abstract: A method of characterizing the protein O-GlcNAcylation site-specificity of an antibody. A method of detecting or quantitating the expression of site-specific O-GlcNAcylated proteins expressed in cells and biological samples. A method of diagnosing cancer in a host based on the cellular expression of site-specific O-GlcNAcylated proteins. A method of screening anti-cancer compounds according to their ability to increase a level O-GlcNAcylation of oncogene or tumor suppressor proteins. Methods of treating cancer in an animal host by administering compounds that increase a level of O-GlcNAcylated c-myc or p53 in cancer cells. A method of distinguishing subclasses of pancreatic cancer according to the sensitivity of pancreatic cancer cells to an imidazole derivative, and a method of personalized pancreatic cancer treatment delivered according to the sensitivity subclasses.Type: GrantFiled: March 3, 2014Date of Patent: June 11, 2019Assignee: Detroit R&D, Inc.Inventors: Hyesook Kim, Sohee Kim
-
Publication number: 20160115224Abstract: A method of producing form-specific anti-peptide antibodies for a wild type protein and its one amino acid mutated protein using a peptide antigen, by obtaining a protein sequence of the wild type protein and its one amino acid mutated protein, selecting a continuous amino acid sequence without any internal cysteine residues that includes the one amino acid mutated sequence and wild type sequence corresponding to the mutated site at the end of the sequence to obtain a synthetic mutation peptide and a synthetic wild type peptide, conjugating the synthetic peptides to a carrier protein, and immunizing an animal to produce antibodies. Methods of detecting cancer and methods of treating cancer.Type: ApplicationFiled: December 11, 2015Publication date: April 28, 2016Applicant: Detroit R&DInventors: Hyesook Kim, Alan Dombkowski
-
Patent number: 9212221Abstract: A method of producing form-specific anti-peptide antibodies for a wild type protein and its one amino acid mutated protein using a peptide antigen, by obtaining a protein sequence of the wild type protein and its one amino acid mutated protein, selecting a continuous amino acid sequence without any internal cysteine residues that includes the one amino acid mutated sequence and wild type sequence corresponding to the mutated site at the end of the sequence to obtain a synthetic mutation peptide and a synthetic wild type peptide, conjugating the synthetic peptides to a carrier protein, and immunizing an animal to produce antibodies. Methods of detecting cancer and methods of treating cancer.Type: GrantFiled: March 3, 2011Date of Patent: December 15, 2015Assignee: Detroit R & D, Inc.Inventor: Hyesook Kim
-
Patent number: 8765641Abstract: An antibody microarray screen including a substrate, monoclonal and polyclonal antibodies that are purified immunoglobins, wherein the antibodies are spotted on predetermined positions on the substrate, and fluids unprocessed for immunoglobulin isolation (e.g., anti-sera, ascites fluids, or hybridoma culture media), wherein the unprocessed fluids are spotted on the predetermined positions on the substrate. Production of drug-metabolizing enzyme antibody microarrays containing closely related cytochromes P450 is disclosed. Methods of manufacturing an antibody microarray, an internal control molecule for use in an antibody microarray, a method of determining optimal spotting concentrations of IgG and a method to increase a detectable signal with microarray analysis are disclosed.Type: GrantFiled: March 18, 2005Date of Patent: July 1, 2014Assignee: Detroit R&D, Inc.Inventors: Hyesook Kim, Alan A. Dombkowski, Raymond F. Novak, Brian B. Haab
-
Patent number: 8409821Abstract: A method of assessing arachidonic acid (AA) metabolites-dependent hypertension by measuring glucuronidated dihydroxyeicosatrienoic acids (DHETs) and DHET metabolites in a biological sample which contains the epitopes unique to DHET (using any methods including GC/MS, LC/MS or ELISA). An example of the glucuronidated DHET metabolite is DHET-alcohols such as omega or omega-1 oxidated DHET and DHET esterified glycerol. The method further includes determining the amount of glucuronidated molecules containing a DHET-specific epitope which is immunoreactive with antibodies produced against DHETs.Type: GrantFiled: March 3, 2010Date of Patent: April 2, 2013Assignee: Detroit R&DInventors: Hyesook Kim, Jorge H. Capdevila, Raymond F. Novak, Deanna Kroetz
-
Publication number: 20110262444Abstract: A method of producing form-specific anti-peptide antibodies for a wild type protein and its one amino acid mutated protein using a peptide antigen, by obtaining a protein sequence of the wild type protein and its one amino acid mutated protein, selecting a continuous amino acid sequence without any internal cysteine residues that includes the one amino acid mutated sequence and wild type sequence corresponding to the mutated site at the end of the sequence to obtain a synthetic mutation peptide and a synthetic wild type peptide, conjugating the synthetic peptides to a carrier protein, and immunizing an animal to produce antibodies. Methods of detecting cancer and methods of treating cancer.Type: ApplicationFiled: March 3, 2011Publication date: October 27, 2011Applicant: Detroit R&D, Inc.Inventor: Hyesook Kim
-
Publication number: 20100159481Abstract: A method of assessing arachidonic acid (AA) metabolites-dependent hypertension by measuring glucuronidated dihydroxyeicosatrienoic acids (DHETs) and DHET metabolites in a biological sample which contains the epitopes unique to DHET (using any methods including GC/MS, LC/MS or ELISA). An example of the glucuronidated DHET metabolite is DHET-alcohols such as omega or omega-1 oxidated DHET and DHET esterified glycerol. The method further includes determining the amount of glucuronidated molecules containing a DHET-specific epitope which is immunoreactive with antibodies produced against DHETs.Type: ApplicationFiled: March 3, 2010Publication date: June 24, 2010Applicant: Detroit R & DInventors: Hyesook Kim, Jorge H. Capdevila, Raymond F. Novak, Deanna Kroetz
-
Patent number: 7695927Abstract: A method to assess arachidonic acid (AA) metabolites-dependent hypertension by measuring glucuronidated dihydroxyeicosatrienoic acids (DHETs) and DHET metabolites in a biological sample which contains the epitopes unique to DHET (using any methods including GC/MS, LC/MS or ELISA) is disclosed. An example of the glucuronidated DHET metabolite is DHET-alcohols such as omega or omega-1 oxidated DHET and DHET esterified glycerol. The method further includes determining the amount of glucuronidated molecules containing a DHET-specific epitope which is immunoreactive with antibodies produced against DHETs. The present invention measuring glucuronidated DHET levels in a biological sample is useful for drug development and monitoring efficiency of drug treatment of a mammal who has AA epoxygenase-, epoxide hydrolase-and/or UDP-glucuronosyl transferase-dependent hypertension.Type: GrantFiled: March 17, 2006Date of Patent: April 13, 2010Assignee: Detroit R & DInventors: Hyesook Kim, Jorge H. Capdevila, Raymond R. Novak, Deanna Kroetz
-
Publication number: 20080058215Abstract: An antibody microarray screen including a substrate, monoclonal and polyclonal antibodies that are purified immunoglobins, wherein the antibodies are spotted on predetermined positions on the substrate, and fluids unprocessed for immunoglobulin isolation (e.g., anti-sera, ascites fluids, or hybridoma culture media), wherein the unprocessed fluids are spotted on the predetermined positions on the substrate. Production of drug-metabolizing enzyme antibody microarrays containing closely related cytochromes P450 is disclosed. Methods of manufacturing an antibody microarray, an internal control molecule for use in an antibody microarray, a method of determining optimal spotting concentrations of IgG and a method to increase a detectable signal with microarray analysis are disclosed.Type: ApplicationFiled: March 18, 2005Publication date: March 6, 2008Applicant: DETROIT R&D, INC.Inventors: Hyesook Kim, Alan A. Dombkowski, Raymond F. Novak, Brian B. Haab
-
Patent number: 7202226Abstract: There is provided a method of augmenting transient protein synthesis in a cell by delivering to the cell mRNA functionally related to protein production. Also provided is a method of augmenting transient protein synthesis in cells by increasing protein synthesis of growth factors from endogenous cellular mRNA and exogenous mRNA delivered to the cells. A treatment for transiently increasing protein production in cells, said treatment comprising mRNA functionally related to protein production is also provided. There is provided a method of augmenting wound healing by delivering mRNA functionally related to wound healing. Further provided is a therapeutic for transiently increasing protein synthesis in cells, said therapeutic comprising mRNA related to protein production.Type: GrantFiled: October 23, 2001Date of Patent: April 10, 2007Assignee: Detroit R & DInventors: Mary Theresa Murray, Scott Alexander Dulchavsky
-
Patent number: 6440682Abstract: A method to assess hypertension by measuring the amount of free and conjugated hydroxyeicosatrienoic acids (DHETS) and metabolites of DHETs, which are metabolites of arachidonic acid (AA) epoxygenases and epoxide hydrolases, in a biological sample which contains the DHETs (using any methods including GC/MS or ELISA) is disclosed. The method further included determining the amount of molecules containing a DHET-specific epitope immunoreactive with antibodies produced against DHETs present in the sample. This amount is compared with a control sample(s). Hypertension is determined through the comparison wherein the amount of increase of free and conjugated DHETs and metabolites of DHETs in the sample isolated from an organism. The present invention also provides a method to assess catalytic activity of AA epoxygenases using immunoassays by measuring the amounts of NADPH-independent epoxyeicosatrienoic acids (EETs) and total (NADPH-dependent+independent) EETs.Type: GrantFiled: May 24, 2000Date of Patent: August 27, 2002Assignee: Detroit R&D Inc.Inventors: Hyesook Kim, Jorge H. Capdevila, Raymond R. Novak, Deanna Kroetz